Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 59Carcinoma, Hepatocellular 46Colorectal Neoplasms 33Stomach Neoplasms 31Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Rectal Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumor 12Triple Negative Breast Neoplasms 11Nasopharyngeal Carcinoma 10Cholangiocarcinoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Melanoma 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × tislelizumab × Clear all
NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
32 enrolled
Genitourinary

Prostatic Neoplasms

NCT06866548 2025-12-04

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Active not recruiting
7 enrolled
Genitourinary

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡